Sonohysterography for evaluation of endometrial abnormalities in breast cancer patients under tamoxifen therapy

Authors

  • Ghorbani , Raheb Epidemiology & Biostatistics Department, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
  • Rahbar, Nahid Abnormal Uterine Bleeding Research Center, Semnan University of Medical Sciences, Semnan, Iran
  • Torshizi , Zahra Abnormal Uterine Bleeding Research Center, Semnan University of Medical Sciences, Semnan, Iran
Abstract:

Introduction: Tamoxifen may have secondary adverse effects on the endometrium. The aim of this study was to investigate the endometrial evaluation in women with breast cancer under tamoxifen therapy with Saline infusion Sonohysterography (SIS). Materials and Methods: This cross-sectional study was performed on 40 breast cancer patients under adjutant tamoxifen (20 mg/day for at least 6 months) therapy referred to Amir-al-Momenin hospital in Semnan, Iran, gynecological clinic, by oncologist during 2018 to 2019. Requested data including individual characteristics and results of vaginal sonography, Sonohysterography, Pathology and   hysteroscopy were recorded in checklist. Results: The mean±SD age of patients was 46.0 ± 6.4 years.  39 patients (97.5%) had amenorrhea. The mean±SD duration of breast cancer was 3.1±1.3 years and the duration of tamoxifen use was 26.3 ± 13.7 months. Sonohysterography was performed without any complication in all patients.  The most important findings in the Sonohysterography were endometrial thickness ≥ 5 mm in 6(15%), echogenic lesion in uterine cavity in 4(10%) and subendometrial cysts in 13 (32.5%) patients. Notably, vaginal sonography found endometrial thickness ≥5 in 16 cases, while Sonohysterography had abnormal findings just in 8 (50%) patients. Overall agreement of Sonohysterography with pathology, hysteroscopy and vaginal sonography was 80%, 80% and 75% respectively. Conclusion: The findings showed that patients under adjutant tamoxifen therapy are at risk for endometrial pathologies such as polyps and hyperplasia. Sonohysterography is well tolerated and has a good overall agreement with pathologic findings and in comparison with vaginal sonography reduces unnecessary invasive interventions.  

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

evaluation of saline sonohysterography findings in patients with breast cancer receiving tamoxifen adjuvant therapy

background: transvaginal ultrasound is one of the most common means to examine endometrial cavity lesions although its negative results are more valuable. saline sonohysterography can reduce the number of false negative rates of endometrial lesions diagnoses in tamoxifen consumers. the objective of this study was to determine the diagnostic values of saline infusion sonohysterography (sis) and ...

full text

Value of sonographic endometrial findings in patients with breast cancer under tamoxifen therapy

Tamoxifen is utilized as adjuvant therapy in women diagnosed with breast cancer. In these patients, despite its positive risk/benefit ratio, tamoxifen may cause secondary effects on the endometrium, with increased risk of malignant diseases. So, the first question to be answered is: “Does tamoxifen increase the incidence of endometrial abnormalities?” The literature presents two meta-analysis-s...

full text

Tamoxifen therapy for breast cancer and endometrial cancer risk.

BACKGROUND Tamoxifen is effective in treating breast cancer, reduces breast cancer incidence among high-risk women, and is associated with increased endometrial cancer risk. This study was designed to examine the possible modifying effects of endometrial cancer risk factors on the tamoxifen-endometrial cancer association. METHODS We conducted a case-control study of endometrial cancer (324 ca...

full text

Trastuzumab therapy for tamoxifen-stimulated endometrial cancer.

A novel in vivo model of tamoxifen-stimulated endometrial cancer was developed and the role of HER-2/neu investigated by using trastuzumab. Tamoxifen-stimulated tumors (ECC-1TAM) were growth stimulated by 17beta-estradiol (E2), tamoxifen, or raloxifene. Trastuzumab inhibited growth of E2-stimulated ECC-1E2 tumors by 50% and tamoxifen-stimulated ECC-1TAM tumors by 100%. ECC-1 tumors expressed fu...

full text

Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen

OBJECTIVE To describe the endometrial pathologic lesions in premenopausal breast cancer patients with a history of tamoxifen (TMX) use. METHODS We retrospectively reviewed the medical records of 120 premenopausal breast cancer patients with a history of TMX use that had undergone a gynecological examination. RESULTS Among 120 patients, 44.2% (n=53) were asymptomatic with an endometrial thic...

full text

changes in thyroid functional tests in breast cancer patients under tamoxifen therapy

abstract background: tamoxifen, a synthetic anti-estrogen agent, is administered as an adjuvant treatment in breast cancer. since various studies have indicated that tamoxifen can change some hormones and bound globolines, controversial results have been achieved using this medicine on thyroid functional tests (tft). the present study was conducted to investigate the effects of tamoxifen on tft...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 22  issue 3

pages  428- 436

publication date 2020-05

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023